机器人辅助单纯剜除术对比标准机器人辅助肾部分切除术治疗低或中复杂度临床T1肾肿瘤:一项随机对照非劣效性试验
本前瞻性随机对照非劣效性试验纳入380例临床T1肾肿瘤患者(RENAL评分<10),随机分为机器人辅助单纯剜除术(RASE)组和标准机器人辅助肾部分切除术(sRAPN)组,主要终点为手术切缘阳性率,非劣效界值7.5%。结果显示RASE组切缘阳性率为2.3%,sRAPN组为3.0%,差异-0.7%(95%CI -4.0%至2.7%),RASE非劣效于sRAPN;RASE组手术时间更短、瘤床缝合率更低,sRAPN组估计失血量更低,两组复发率无差异。
要点
- RASE组切缘阳性率2.3%,sRAPN组3.0%,差异-0.7%(95%CI -4.0%至2.7%),在7.5%界值内非劣效。
- RASE组中位手术时间145分钟 vs sRAPN组155分钟(p=0.018),瘤床缝合率8.9% vs 43%(p<0.001)。
- sRAPN组估计失血量显著低于RASE组(p=0.046),两组复发率无差异(p>0.9)。
核心结论
- 对于低至中复杂度肾肿瘤,RASE在切缘阳性率方面非劣效于sRAPN。
- 需要长期随访才能就肿瘤学结局得出结论。
研究设计与样本
- 前瞻性、随机、对照、非劣效性试验,纳入380例年龄18-80岁、新诊断、散发性、单侧临床T1肾肿瘤(RENAL评分<10)患者,随机分配至RASE组(n=190)或sRAPN组(n=190)。
- 主要终点为切缘阳性率,非劣效界值设为7.5%,研究注册于ClinicalTrials.gov(NCT03624673)。
主要发现
- 意向性治疗分析中,恶性肿瘤患者RASE组切缘阳性率为2.3%,sRAPN组为3.0%,差异-0.7%(95%CI -4.0%至2.7%),RASE在7.5%界值内非劣效于sRAPN。
- 符合方案分析同样显示RASE的非劣效性。
- RASE组中位手术时间145分钟 vs sRAPN组155分钟(p=0.018),瘤床缝合率8.9% vs 43%(p<0.001)。
- sRAPN组估计失血量显著低于RASE组(p=0.046)。
- 两组复发率无差异(p>0.9)。
关键数值与推荐
- 非劣效性定义为RASE对比标准RAPN的切缘阳性率差异的95%置信区间上限<7.5%。
- RASE组切缘阳性率2.3% vs sRAPN组3.0%,差异-0.7%(95%CI -4.0%至2.7%)。
- RASE组中位手术时间145分钟 vs sRAPN组155分钟(p=0.018)。
- RASE组瘤床缝合率8.9% vs sRAPN组43%(p<0.001)。
- sRAPN组估计失血量显著低于RASE组(p=0.046)。
临床怎么用
- 对于低至中复杂度临床T1肾肿瘤,RASE在切缘阳性率方面非劣效于sRAPN。
- RASE与更短的手术时间和更低的瘤床缝合率相关。
- sRAPN与更低的估计失血量相关。
- 需要长期随访以评估肿瘤学结局。
局限性
- 需要长期随访才能就肿瘤学结局得出结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although partial nephrectomy has become the gold standard for T1 renal tumors whenever technically feasible, simple enucleation has shown superior results. To the best of our knowledge, no randomized controlled trials comparing these two surgical approaches have been published. OBJECTIVE: To compare the surgical margin status for robot-assisted simple enucleation (RASE) and standard robot-assisted partial nephrectomy (sRAPN) for clinical T1 renal tumors. DESIGN, SETTING, AND PARTICIPANTS: This is a prospective, randomized, controlled, noninferiority trial. A total of 380 patients aged 18-80 yr with newly diagnosed, sporadic, unilateral clinical T1 renal tumors (RENAL score <10) were enrolled and randomized to RASE or sRAPN. The primary endpoint was the positive surgical margin (PSM) rate, with a noninferiority margin of 7.5% set. The study was registered on ClinicalTrials.gov (NCT03624673). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We defined noninferiority for RASE versus standard RAPN as an upper 95% confidence interval (CI) bound of <7.5% for the difference in the proportion of patients with a PSM. RESULTS AND LIMITATIONS: A cohort of 380 patients was enrolled and randomly assigned to RASE (n = 190) or sRAPN (n = 190). On intention-to-treat analysis for patients with malignant tumors, 2.3% of patients in the RASE group and 3.0% in the sRAPN group had a PSM. The RASE group showed noninferiority to the sRAPN group within a 7.5% margin (difference -0.7%, 95% CI -4.0% to 2.7%). Per-protocol analysis also demonstrated noninferiority of RASE. The RASE group had a shorter median operative time (145 vs 155 min; p = 0.018) and a lower rate of tumor bed suturing (8.9% vs 43%; p < 0.001) in comparison to the sRAPN group. Estimated blood loss was considerably lower in the sRAPN group than in the RASE group (p = 0.046). The rate of recurrence did not differ between the groups (p > 0.9). CONCLUSIONS: RASE for the management of low- to intermediate-complexity tumors is noninferior to sRAPN in terms of the PSM rate. Long-term follow-up is needed to draw conclusions regarding oncological outcomes. PATIENT SUMMARY: We carried out a trial to compare simple tumor enucleation versus partial nephrectomy for renal tumors. The outcome we assessed was the proportion of patients with a positive surgical margin. Our results show that simple tumor enucleation is not inferior to partial nephrectomy for this outcome. Longer follow-up is needed to assess other cancer control outcomes.
引用
- Lu Q, Zhao X, Zhang S, et al. Robot-assisted Simple Enucleation Versus Standard Robot-assisted Partial Nephrectomy for Low- or Intermediate-complexity, Clinical T1 Renal Tumors: A Randomized Controlled Noninferiority Trial. Eur Urol Oncol. 2023. PMID: 37598032. doi:10.1016/j.euo.2023.07.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。